Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 130,162 |
|
|||||
| News | - | ||||||
| Day High | 2.12 | Low High |
|||||
| Day Low | 2.03 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Poseida Therapeutics Inc | PSTX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.03 | 1.46% | 2.08 | 10:35:56 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 2.03 | 2.03 | 2.12 | 2.05 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 995 | 130,162 | $ 2.07 | $ 268,849 | - | 1.54 - 4.27 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 10:35:56 | 100 | $ 2.08 | USD |
Poseida Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 198.77M | 96.49M | - | 64.7M | -123.43M | -1.28 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Poseida Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PSTX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.00 | 2.2699 | 1.95 | 2.09 | 469,855 | 0.08 | 4.00% |
| 1 Month | 3.29 | 3.35 | 1.91 | 2.48 | 513,048 | -1.21 | -36.78% |
| 3 Months | 3.33 | 4.27 | 1.91 | 3.25 | 727,764 | -1.25 | -37.54% |
| 6 Months | 2.13 | 4.27 | 1.83 | 3.03 | 803,094 | -0.05 | -2.35% |
| 1 Year | 2.55 | 4.27 | 1.54 | 2.63 | 818,177 | -0.47 | -18.43% |
| 3 Years | 9.01 | 11.10 | 1.54 | 3.85 | 576,572 | -6.93 | -76.91% |
| 5 Years | 17.00 | 17.62 | 1.54 | 4.87 | 530,244 | -14.92 | -87.76% |
Poseida Therapeutics Description
| Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet delivery technology. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours. |
